Gregory Fusco is Chief Executive Officer and Chief Medical Officer at Epividian. Mr. Fusco studied microbiology at the University of Michigan, epidemiology at the University of Michigan School of Public Health and medicine at the Michigan State University College of Human Medicine. He trained in anatomic pathology at the University of Pittsburgh. His epidemiology experience spanned both government and industry appointments. He was a site coordinator (Detroit) for the Adult Spectrum of Disease in HIV Study, a national Centers for Disease Control and Prevention sponsored study. This study contributed to the 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. He has 18 years of experience in the pharmaceutical industry leading Phase 1, 2, 3, and 4 clinical trials in multiple therapeutic disciplines as well as leading epidemiology and outcomes research groups and pharmacoepidemiologic, pharmacovigilance, risk management and signal detection efforts in development programs for both small molecules and biologics. His therapeutic development and life cycle management experience includes Infectious Disease (HIV/HCV), gastrointestinal disease (UC/CD, EE, GERD), metabolic disease (diabetes), cardiovascular disease (hypertension), dermatologic disease (psoriasis), and renal & hematologic disease (anemia of CKD). Well published in multiple therapeutic disciplines, he continues to develop systems for the improvement of medical practice, clinical development and adverse event management and signaling. Additional efforts include the development and identification of biomarker profiles utilizing observational (big data) databases to assist in the medical management of patients and the design and conduct of clinical trials.
